Full-Time

Process Development Associate

Pilot Plant

Posted on 4/10/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$80k - $89.2k/yr

+ Bonus + Stock-based long-term incentives

Junior, Mid

Cambridge, MA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Visio
Word/Pages/Docs
Tableau
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • High school diploma / GED and 4 years of manufacturing, engineering, or process development experience OR
  • Associate’s degree and 2 years of manufacturing, engineering, or process development experience OR
  • Bachelor’s degree
Responsibilities
  • Perform and monitor cell culture and purification operations up to the 200L pilot plant scale utilizing such equipment as rocking and single-use bioreactors, and single-use chromatography and filtration systems (TFF, VF, UFDF).
  • Document work in electronic lab notebooks per GDP principles while following appropriate SOPs.
  • Generate, analyze, and summarize process data to identify and mitigate challenges to future commercial processes, and support new technology development, new product introductions, and facility tech transfers.
  • Use tools such as Biovia Workbook, Emerson DeltaV, PI Vision, Smartsheet, Spotfire, Tableau, and the Microsoft suite (Outlook, Word, Excel, PowerPoint, Visio, Sharepoint, Teams).
  • Demonstrate the Amgen Values and contribute to a culture of safety.
Desired Qualifications
  • Bachelor's degree in Chemical, Biomedical, or related Engineering, Biology, Chemistry, Physics, or other relevant life science.
  • Experience with mammalian cell culture and/or protein purification.
  • Basic understanding of physical and scientific principles underlying cell culture, protein chromatography, and filtration.
  • Demonstrated ability to identify and solve problems by applying scientific and engineering principles, preferably in a process development environment.
  • An established record of championing a culture of safety in a lab or manufacturing setting.
  • Knowledge in troubleshooting process equipment issues including automation control strategies.
  • Specific hands-on operational experience with control systems such as DeltaV.
  • Experience in leading Operational Excellence (OE) efforts to drive efficiency and safety.
  • Proven ability to learn new systems and applications and various new technologies.
  • Experienced in performing bioprocess unit operations in cell culture and/or purification.
  • Experience working with process data analysis and interpretation.
  • Strong written and verbal communication skills; the ability to communicate complex ideas in a simple manner.
  • Strong interpersonal skills; the ability to work flexibly in a dynamic and collaborative environment with diverse team members.
  • Strong computer/digital skills with a demonstrated ability to quickly learn new software.
  • Growth mindset and results-oriented.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care by providing effective therapeutic solutions and expanding its pipeline of potential new treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.

INACTIVE